TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00370838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: The initial dose of levetiracetam was 10 mg/kg/day, divided twice daily (rounded to the closest unit of 250 mg). The dose was increased weekly by 5-10 mg/kg/day, to a maximum dose of 50 mg/kg/day (or 2,500 mg/day), if deemed necessary for tic suppression. In any individual, dose escalation may have proceeded more slowly, or the dose may have been reduced as necessary. No changes in dosage occurred during the final week of either treatment phase.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: The initial dose of clonidine was 0.05 mg, twice daily. If needed for tic suppression, the dose was increased weekly by 0.05-0.1 mg, with a maximum dose of 0.4 mg per day. In any individual, dose escalation may have proceeded more slowly, or the dose may have been reduced as necessary. No changes in dosage occurred during the final week of either treatment phase.
Study: NCT04463667

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: Collect all basic information including intrahepatic fat and fibrosis severity, and assign them to the exercise intervention group (n = 80) and the observation group (n = 20) after conditional screening.
Study: NCT03156439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIS-001 ER
Description: BIS-001 ER is an extended release formulation of the nutritional supplement Huperzine A.
Study: NCT00428844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daptomycin
Description: 6 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daptomycin
Description: 8 mg/kg
Study: NCT02119780

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YVOIRE® contour
Description: YVOIRE® contour injection into the anteromedial malar region

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane SubQ™
Description: Restylane SubQ™ injection into the anteromedial malar region
Study: NCT00681772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: 5mg, 10mg or 20mg taken 1 hours before sexual intercourse
Study: NCT00754312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNDX-275
Study: NCT01368874

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera® System treatment
Description: Single treatment of focused ultrasound energy delivered below the surface of the skin.
Study: NCT00754312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNDX-275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNDX-275
Study: NCT04694079

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group 1, CMR-guided/aided VT ablation
Description: Ablation of the anatomical channels of heterogeneous tissue within the scar

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group 2, CMR-aided VT ablation
Description: Ablation of the electrical conduction channels within the scar

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group 3, Electroanatomical guided ablation
Description: Ablation guided by an electro-anatomical system without the aid of CMR
Study: NCT02993133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cellcept® in autoimmune bullous dermatoses
Description: The administration will follow the recommendations for the use of Cellcept® in autoimmune bullous dermatoses
Study: NCT02386605

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing and Cognitive Behavioral Therapy
Description: group-based recovery-oriented Motivational Interviewing combined with cognitive-behavioral therapy to target the negative symptoms of schizophrenia

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Skills
Description: Relaxation and mindfulness skills training group for comparison condition for negative symptoms of schizophrenia
Study: NCT01809158

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: minocycline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03014700

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fibrinogen Concentrate
Description: Subject will be administered Fibrinogen Concentrate to control bleeding after open heart surgery when randomized to Fibrinogen Concentrate group

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cryoprecipitate
Description: Subject will be administered Cryoprecipitate to control bleeding after open heart surgery when randomized to Cryoprecipitate group
Study: NCT00428844

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vancomycin
Description: 1 gram

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: teicoplanin
Description: 6 mg/kg; used only at UK sites

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nafcillin
Description: 1-2 gram

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxacillin
Description: 1-2 gram

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: flucloxacillin
Description: 1-2 mg
Study: NCT02794545

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cART course
Description: The investigators would start regular cART course immediately for early infection patients to achieve functional cure.
Study: NCT04365452

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Invia Motion
Description: Invia Motion NPWT system at cesarean delivery
Study: NCT00552604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standardized cannabis extract
Description: Cannabis extract (delta-9-THC 2.5mg, CBD 1.25 mg per capsule), flexible dosing between 5 mg and 25 mg THC/d, administered twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules, twice daily
Study: NCT02471625

Intervention type: DEVICE
Intervention: ClearView Scanning
Study: NCT00786487

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glycerol
Description: glycerol infusion (2.25 g/100ml) will be administered at 1.5 ml/min,

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glycerol
Description: glycerol infusion (2.25 g/100ml) will be administered at 1.5 ml/min,
Study: NCT00715325

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Protectiscop CS
Description: Patients who are indicated for screening colonoscopy will be recruited into the trial. The ProtectiScope CS sleeve is assembled on the colonoscope.standard colonoscopy is performed. Subjects will be followed for 1-month post procedure.
Study: NCT02732483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endo-Clot(TM)
Description: The patients agreed in this study, bleeding control will going to be done with Endo-Clot(TM)
Study: NCT03081507

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SM-LHW
Description: Will not receive additional follow-up from the LHW, but will be encouraged during the session to make an appointment with their provider to schedule a mammogram and Pap test, or to consult the MARHABA webpage for information on low-cost and culturally appropriate referral sources of screening. Individuals assigned to this arm who did not attend an educational seminar will be mailed a packet containing a palm card, brochure, and letter encouraging them to speak with their provider about breast and cervical cancer screening and/or going to the MARHABA webpage. LHWs will complete a follow-up survey with participants by phone or in-person at 4 months after baseline

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PN-LHW
Description: PNLHW participants will receive three planned contacts with LHWs that focus on navigation for obtaining mammogram and/or Pap testing.The initial contact will be made by phone and will focus on motivating participants to make an appointment with their primary care provider and/or obstetrician/gynecologist (OB/GYN), as well as provide information on low-cost or free care if necessary. The second contact will discuss the process of going to the appointment and the third contact will focus on the process of obtaining and interpreting. The second and third contacts will be either made by phone or in-person, depending on participant needs.
Study: NCT00734279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate - Early Puberty Leuprolide Visit
Description: Dose of 10 mcg/kg Sub cutaneous once at 0800 on day 2 of the Early Puberty Luprolide Visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate - Early Puberty Leuprolide Visit
Description: Dose of 10 mcg/kg Sub cutaneous once at 0800 on day 2 of the Early Puberty Luprolide Visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganirelix - Early Puberty Ganirelix Visit
Description: Dose of 2.5 mcg/kg Sub-cutaneous once at 17:30 on day 1 of the Early Puberty Ganirelix Visit and once at 08:00 on day 2 of the Early Puberty Ganirelix Visit
Study: NCT03942029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3154207 Capsule
Description: Administered orally as capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3154207 Tablet
Description: Administered orally as tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3154207 Tablet
Description: Administered orally as tablet
Study: NCT03417986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEP
Description: For safety reasons the clinical trial will first enroll 14 subjects (7 patients and 7 healthy volunteers) for Group 1a receiving 26 mg TEP daily for 4 days with subsequent safety evaluation, based on adverse events and the safety parameters discussed in the protocol. A second set of patients (Group 1b), which will receive a higher dosage of 52 mg per day for 4 days will be enrolled optionally after recommendation to continue and subsequently treatment Group 2 with a treatment paradigm of 26 mg TEP daily for 54 days will start.~Subjects eligible for participation are subjects with newly diagnosed (within last 12 month) early-to-mild dementia due to AD and healthy volunteers who fulfill all inclusion criteria and have none of the exclusion criteria present at screening.
Study: NCT00734279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganirelix - Early Puberty Ganirelix Visit
Description: Dose of 2.5 mcg/kg Sub-cutaneous once at 17:30 on day 1 of the Early Puberty Ganirelix Visit and once at 08:00 on day 2 of the Early Puberty Ganirelix Visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganirelix - Delayed Puberty Ganirelix Visit
Description: Ganirelix is administered at a dose of 2.5 mcg/kg sub cutaneous at 17:30 on day 1 and once at 08:00 on day 2 of the Ganirelix Delayed Puberty Visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganirelix - Delayed Puberty Ganirelix Visit
Description: Ganirelix is administered at a dose of 2.5 mcg/kg sub cutaneous at 17:30 on day 1 and once at 08:00 on day 2 of the Ganirelix Delayed Puberty Visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate- Delayed Puberty Leuprolide Visit
Description: Leuprolide acetate is given at a dose of10 mcg/kg at 0800 on day 2 of the Delayed Puberty Leuprolide Visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate- Delayed Puberty Leuprolide Visit
Description: Leuprolide acetate is given at a dose of10 mcg/kg at 0800 on day 2 of the Delayed Puberty Leuprolide Visit
Study: NCT00690014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: probenecid
Description: 500 mg q 6 hrs
Study: NCT02461901

Intervention type: OTHER
Intervention: Environmental sampling
Description: Sampling of five sites in the patient's immediate environment for C. difficile spores
Study: NCT02461901

Intervention type: OTHER
Intervention: Environmental sampling
Description: Sampling of five sites in the patient's immediate environment for C. difficile spores

Intervention type: OTHER
Intervention: Skin swab sampling
Description: Collection of swabs from three sites on the skin for C. difficile spores

Intervention type: OTHER
Intervention: Skin swab sampling
Description: Collection of swabs from three sites on the skin for C. difficile spores

Intervention type: OTHER
Intervention: Fecal sampling
Description: Collection of fecal samples for C. difficile spores

Intervention type: OTHER
Intervention: Fecal sampling
Description: Collection of fecal samples for C. difficile spores
Study: NCT01985581

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Guanfacine extended release

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine extended release

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Stimulant therapy
Description: patient will continue to take stable dosage of usual stimulant therapy (Ritalin, Ritalin SR, Biphentin, Concerta, Vyvanse, Adderall or Dexedrine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stimulant therapy
Description: patient will continue to take stable dosage of usual stimulant therapy (Ritalin, Ritalin SR, Biphentin, Concerta, Vyvanse, Adderall or Dexedrine)
Study: NCT03942029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3154207 Tablet
Description: Administered orally as tablet
Study: NCT01558388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus
Description: Lactobacillus acidophilus 500 million colony-forming units/tablets. One vaginal tablet daily for 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One vaginal tablet daily for 10 days.
Study: NCT03054545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iguratimod
Description: Iguratimod 25mg twice a day, oral administrated.
Study: NCT02760446

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CAM-ICU.fr
Description: Neuropsychological testing
Study: NCT03554226

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NeuroPsychiatric Inventory Clinician (NPI-C)
Description: All scales that will be administered to the patient during this study, (ADL, MMSE, QoL-AD, NPI and CMAI), are the subject of recommendations for the management of patients with AD (HAS 2009, HAS 2011)
Study: NCT03575312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enrofloxacin
Description: dermal application, inhalation rsp. oral administration of Enrofloxacin
Study: NCT03800927

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Long duration ultrasound
Description: Low-intensity long duration ultrasound treatment

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Long duration ultrasound
Description: Low-intensity long duration ultrasound treatment
Study: NCT00891644

Intervention type: OTHER
Intervention: Case Management
Description: Clinical personnel at each AMTU site may work with other personnel from organizations authorized to have access to personal health information to identify clients identified as HIV positive within the past 6 - 18 months.~Initial contact will be made by persons at source organizations who are authorized to have access to personal health information. Persons so authorized will explain the nature of the research study and request permission from the client for subsequent contact by research personnel from the AMTU site. If permission for contact is received, research personnel at each site will attempt calls as specified by the potential participant or at random times (before 12:00 pm; between 12:00 - 4:00 pm; and between 4:00 - 10:00 pm) for no more than 10 attempts.

Intervention type: OTHER
Intervention: Snowball sampling
Description: Snowball sampling assumes that social networks of HIV sero-positive persons in treatment may overlap with those of HIV sero-positive persons not in treatment.~When a site is assigned to identify HIV positive adolescents not in care by snowball sampling, all HIV positive persons in care at the site will be invited to refer other adolescents known to them as HIV positive, but not in care, for possible participation in the study.~Printed information containing a brief description of the research in English and in Spanish and contact information of site study personnel will be provided to in-care adolescents at the site for distribution to those known HIV positive adolescents who are not in care.

Intervention type: OTHER
Intervention: Referral Lists
Description: AMTU staff will develop lists of potential participants at their sites who have had an initial HIV-related health care visit but not received additional visits within the 12 mos prior the list (or before protocol screening) or have completed initial and follow up visits but dropped out of care for 12 or more mos. Back-up lists will be made of potential participants who have gone 9-12 mos and 6-9 mos without a visit. Clinical staff at each AMTU may work with staff from other organizations authorized to access personal health information to find potential participants. 1st contact will be made by persons at source organizations who are authorized to access personal health information. Authorized staff will explain the study and ask permission for contact by research staff at the AMTU site. If so, research staff will attempt calls as specified by the potential participant or at random (before 12 pm; between 12-4 pm; and between 4-10 pm) for no more than 10 attempts.
Study: NCT02392962

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Static Stretching
Description: To analyze the immediate effects of static stretching on performance of sprinters

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Stretching
Description: To analyze the immediate effects of dynamic stretching on performance of sprinters
Study: NCT02261714

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TG01
Description: TG01 and GM-CSF will be administered on days 1, 8, 15, 22 and 36. TG01 alone will also be given on days 36 and 50 for DTH assessment. Gemcitabine will start at least 3 weeks after TG01/GM-CSF and will be given on days 1, 8 and 15 of a four-weeks cycle up to 6 cycles in total.~Once chemotherapy is completed, GM-CSF and TG01 injections will resume and will be given every 4 weeks from the end of the chemotherapy period up to week 52 (plus once at week 5 post-chemotherapy) and then every 12 weeks from week 52 to week 104. TG01 alone will be given 8 weeks after the end of chemotherapy for DTH assessment.~TG01 will be given at a dose of 0.70 mg/injection and GM-CSF will be given at a dose of 30 micrograms both as intradermal injections.~Gemcitabine will be given at a dose of 1000 mg/m2 iv over 30 minutes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TG01
Description: For patients not able to start TG01 quickly after surgery, the vaccination can start at the same time as the chemotherapy as long as they start within 12 weeks from surgery. Gemcitabine will start at the same time as TG01/GM-CSF and will be given on days 1, 8 and 15 of a four-weeks cycle up to 6 cycles in total.~TG01 will be given at a dose of 0.70 mg/injection and GM-CSF will be given at a dose of 30 micrograms both as intradermal injections.~Gemcitabine will be given at a dose of 1000 mg/m2 iv over 30 minutes
Study: NCT03302013

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vanguard XP Bi-cruciate Retaining Knee Replacement System
Description: Newer design of knee replacement retaining the Anterior Cruciate Ligament as well as the Posterior Cruciate Ligament.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vanguard CR Single Cruciate Retaining Knee System
Description: Current 'gold standard' for total knee replacement which retains Posterior Cruciate Ligament but sacrifices the Anterior Cruciate Ligament, instead providing artificial support.
Study: NCT00785109

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin K supplementation
Description: Daily vitamin K supplementation per os (2 mg once a day)Experimental 1 Placebo Experimental 2

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin K supplementation
Description: Daily vitamin K supplementation per os (2 mg once a day)Experimental 1 Placebo Experimental 2
Study: NCT01163279

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Real world strategy approach
Description: The key features of the protocol are: i. Participants are actively engaged in selecting their treatment goals. The research clinician will work with the participants to identify five specific, measurable real-world goals using a standardized semi-structured interview, the Canadian Occupational Performance Measure. Three of these will be training goals, two will not be trained but evaluated post-intervention for evidence of generalization and transfer to non-trained tasks; ii. A global problem solving approach is used (Goal- Plan- Do- Check). Participants are guided by the trainer to apply this strategy to their goals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial Education
Description: The active comparator uses an information-based format and is designed to engage participants without providing any specific training techniques or strategies. During weekly sessions, participants will receive factual information on brain structure and function, age-related cognitive changes, and general brain health issues and will spend time doing non-specific cognitive exercises including crossword and Sudoku puzzles. Homework will consist of reading assignments related to the session topics.
Study: NCT01971450

Intervention type: DRUG
Intervention: Iloprost (Ventavis, BAYQ6256)
Study: NCT02784821

Intervention type: DRUG
Group type: OTHER
Intervention: Antibiotic
Description: Babies that are assigned to antibiotics receive therapy based on the clinical team's discretion.

Intervention type: OTHER
Group type: OTHER
Intervention: Gastric fluid
Description: Microbiome evaluated using gastric aspirate.

Intervention type: OTHER
Group type: OTHER
Intervention: Gastric fluid
Description: Microbiome evaluated using gastric aspirate.

Intervention type: OTHER
Group type: OTHER
Intervention: Gastric fluid
Description: Microbiome evaluated using gastric aspirate.

Intervention type: OTHER
Group type: OTHER
Intervention: Gastric fluid
Description: Microbiome evaluated using gastric aspirate.

Intervention type: OTHER
Group type: OTHER
Intervention: Breast milk
Description: Microbiome will be evaluated using mother's breast milk.

Intervention type: OTHER
Group type: OTHER
Intervention: Breast milk
Description: Microbiome will be evaluated using mother's breast milk.

Intervention type: OTHER
Group type: OTHER
Intervention: Breast milk
Description: Microbiome will be evaluated using mother's breast milk.

Intervention type: OTHER
Group type: OTHER
Intervention: Breast milk
Description: Microbiome will be evaluated using mother's breast milk.

Intervention type: OTHER
Group type: OTHER
Intervention: Stool samples
Description: Microbiome will be evaluated using infant's stool.
Study: NCT01368874

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera® System treatment
Description: Single treatment of focused ultrasound energy delivered below the surface of the skin.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera® System treatment
Description: Single treatment of focused ultrasound energy delivered below the surface of the skin.